Business context and reporting period
This is Gemini Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2022, filed November 10, 2022—not a filing by Disc Medicine, Inc. Gemini was a clinical-stage biotechnology company with no product revenue. It discontinued both Phase 2a GEM103 trials in January 2022; GEM307 remained preclinical. Following a major restructuring, Gemini’s business was focused on its proposed merger with Disc.
Financial results and liquidity
Amounts below are in millions except per-share data. Gemini reported no revenue, gross profit, or operating margin; it had no approved products or product sales.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $0.4 | $13.5 | $12.8 | $36.1 |
| General and administrative expense | $3.3 | $5.0 | $13.3 | $15.2 |
| Total operating expenses | $3.7 | $18.5 | $26.1 | $51.3 |
| Net loss | $3.3 | $18.6 | $25.6 | $54.0 |
| Basic and diluted loss per share | $0.08 | $0.43 | $0.59 | $1.37 |
| Net cash used in operating activities | Not separately stated for the quarter | $29.8 | $47.0 |
At September 30, 2022, cash and cash equivalents were $101.7 million, versus $136.6 million at December 31, 2021. Total assets were $106.0 million, current liabilities $1.5 million, and stockholders’ equity $104.6 million. Gemini had no debt outstanding: it repaid its term loan in full in September 2022. Working capital was approximately $103.2 million. Management believed available cash would fund planned operations for at least twelve months from the filing date, but said that estimate depended on assumptions and could change with the merger or other strategic outcomes.
Changes versus the prior comparable period
- Q3 net loss narrowed by $15.3 million year over year, primarily as operating expenses fell $14.7 million. R&D expense declined $13.0 million, reflecting reduced clinical activity, lab-space elimination, and lower headcount after restructuring.
- For the first nine months, net loss narrowed by $28.4 million and operating expenses fell $25.1 million, reflecting reduced R&D activity and restructuring. A $1.0 million employee retention credit also reduced 2022 expenses.
- Operating cash use improved by $17.2 million year over year for the first nine months. Cash and cash equivalents declined $34.9 million from year-end 2021; financing cash use included $5.4 million of net loan repayments and other financing activity.
- Interest income increased as cash earned higher returns. Prior-year interest expense included accretion on convertible-note discounts, and 2021 included a $0.7 million loss on conversion of convertible notes.
Outlook, transaction, risks, and unusual items
- The August 2022 merger agreement contemplated Gemini’s subsidiary merging into Disc, with Disc surviving as a wholly owned subsidiary. The filing expected closing in Q4 2022, subject to both companies’ stockholder approvals, an effective Form S-4 registration statement, Nasdaq listing approval, and other conditions. This was an expectation at the filing date, not confirmation of completion.
- Before the merger, Disc investors had agreed to purchase approximately $53.5 million of Disc shares, subject to conditions. The filing estimated former Disc holders would own about 72% and pre-merger Gemini holders about 28% of the combined company before the concurrent financing, subject to adjustment.
- Gemini stockholders were to receive contingent value rights (CVRs) tied to proceeds from disposition of certain pre-merger Gemini assets, net of permitted deductions. The filing cautioned that the assets might not generate proceeds and the CVRs could expire valueless.
- Merger termination could trigger a $3.0 million fee payable by Gemini or a $7.8 million fee payable by Disc in specified circumstances; expense reimbursement of up to $0.75 million could also apply. Gemini had capitalized $1.2 million of deferred transaction costs by quarter-end.
- If the merger did not close, Gemini might pursue another transaction or dissolution and liquidation. Management said future operations were highly dependent on the merger’s success. As of November 4, Gemini reported only four full-time and one part-time employee, creating execution and retention risks.
- Risks included merger delay or failure, transaction costs, potential litigation, employee departures, restrictions on business activity while the agreement remained in effect, stock-price volatility, and the possibility of dilution or limited recovery in a liquidation. The company also cited inflation, geopolitical uncertainty, capital-market disruption, and COVID-19-related uncertainty; it reported no related asset impairment to date.
- Gemini recorded a $1.0 million employee retention credit in the first half of 2022 and had $0.9 million receivable at September 30. It paid a $0.4 million end-of-term charge when prepaying its loan.
Most important facts for investors to verify
- Confirm the filing identity: it is Gemini Therapeutics’ 10-Q, notwithstanding the request metadata naming Disc Medicine.
- Check subsequent filings for whether and when the merger closed, final ownership and exchange-ratio adjustments, and the status of the concurrent financing.
- Review the final CVR agreement, asset-disposition terms, deadlines, deductions, and any proceeds or distributions.
- Assess actual cash use and remaining liquidity against management’s stated twelve-month runway, especially given the merger outcome and ongoing transaction costs.
- Verify the consequences of a failed transaction, including any termination fee, alternative plans, liquidation decision, and potential value available to stockholders.